Management of Postpartum Hemorrhage

Definition and Diagnosis

The World Health Organization (WHO) defines postpartum hemorrhage (PPH) as blood loss of more than 500 mL after vaginal birth or 1000 mL after caesarean section, or any blood loss sufficient to compromise hemodynamic stability 1
PPH is the leading cause of maternal mortality globally, with most deaths occurring within the first 24 hours after birth 2

The WHO strongly recommends early use of intravenous tranexamic acid (within 3 hours of birth), in addition to standard care for women with clinically diagnosed postpartum hemorrhage following vaginal birth or caesarean section 1, 3
TXA should be administered at a fixed dose of 1 g (100 mg/mL) intravenously at 1 mL/min (over 10 minutes) 1
A second dose of 1 g should be given if bleeding continues after 30 minutes or restarts within 24 hours of the first dose 1
TXA should be given in all cases of PPH, regardless of whether bleeding is due to genital tract trauma or other reasons, including uterine atony 1, 4
TXA must be administered within 3 hours of birth, as delay reduces benefit by approximately 10% for every 15 minutes 3, 5
TXA should not be given beyond 3 hours after birth as it may be potentially harmful 3

The standard treatment package for PPH includes fluid replacement 4, treatment with uterotonics, monitoring of vital signs 4, non-surgical interventions (bimanual compression, intrauterine balloon tamponade, non-pneumatic antishock garment, external aortic compression) 4, and surgical interventions (brace sutures, arterial ligation, or hysterectomy) when necessary 4
Sequential use of interventions should start with less invasive approaches, moving toward more invasive interventions as required 3, 4
Health facilities providing emergency obstetric care need appropriate supplies and trained staff to administer TXA safely by intravenous infusion 3

The American College of Obstetricians and Gynecologists recommends early administration of intravenous tranexamic acid (within 3 hours of birth) at a dose of 1g over 10 minutes, alongside oxytocin administration (5-10 IU IV/IM) to reduce maternal morbidity and mortality 6
Oxytocin administration of 5-10 IU slow IV or intramuscular infusion immediately postpartum is recommended to reduce PPH incidence, with the IV route being more effective than IM for PPH prevention 7, 8

The European Society of Cardiology recommends fluid replacement with physiologic electrolyte solutions, such as IV fluid resuscitation, to manage postpartum hemorrhage 9

Manual removal of placenta should not be routinely performed except in cases of severe and uncontrollable PPH, as recommended by the American Society of Anesthesiologists 8, 10

The European Society of Cardiology recommends careful planning of delivery in women with mechanical heart valves on anticoagulation to minimize bleeding risk, and notes that prostaglandin F analogues are useful to treat PPH unless an increase in pulmonary artery pressure is undesirable 9
Methylergonovine is contraindicated in patients with hypertension due to risk of vasoconstriction and hypertension (>10% risk), as stated by the European Society of Cardiology 9

The European Society of Cardiology recommends continuing hemodynamic monitoring for at least 24 hours after delivery, as this period has significant hemodynamic changes and fluid shifts that may precipitate heart failure in women with structural heart disease 9

The American College of Radiology recommends uterine tamponade with either packing or balloon catheter as a first-line conservative measure alongside uterotonic medications for postpartum hemorrhage, with a success rate of 90% when properly placed 11, 12

The American College of Radiology positions balloon tamponade as a conservative mechanical intervention to be implemented after failure of uterotonic medications but before proceeding to interventional radiology or surgery, with a high success rate of 79.4% to 88.2% in uterine atony cases 11, 12

For anticoagulated patients, active management of third stage with uterotonics (oxytocin) is critical to reduce bleeding risk, as the primary mechanism of placental bed hemostasis is myometrial contraction (not coagulation), so oxytocin remains effective in anticoagulated patients, and minimize trauma and ensure adequate uterine contraction to compensate for impaired hemostasis 13, 14
The American College of Obstetricians and Gynecologists recommends that oxytocin administration must be combined with other active management strategies to optimize outcomes, including tranexamic acid administration and uterine massage, in patients with high risk of postpartum hemorrhage 13, 14

Higher oxytocin doses (up to 80 IU) are associated with a 47% reduction in postpartum hemorrhage compared to lower doses (10 IU), with an adjusted odds ratio of 0.53, and a moderate-dose regimen (30 IU) shows intermediate benefit with a 43% reduction in hemorrhage (OR 0.57) 13, 14